Biocure Technology Inc
Biocure Technology Inc. engages in exploration of mineral properties. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Biocure Technology Inc (BICTF) - Net Assets
Latest net assets as of September 2025: $1.61 Million USD
Based on the latest financial reports, Biocure Technology Inc (BICTF) has net assets worth $1.61 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.02 Million) and total liabilities ($413.72K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.61 Million |
| % of Total Assets | 79.52% |
| Annual Growth Rate | 16.92% |
| 5-Year Change | N/A |
| 10-Year Change | -24.69% |
| Growth Volatility | 145.02 |
Biocure Technology Inc - Net Assets Trend (2007–2024)
This chart illustrates how Biocure Technology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biocure Technology Inc (2007–2024)
The table below shows the annual net assets of Biocure Technology Inc from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.34 Million | -16.37% |
| 2023-12-31 | $1.60 Million | +168.87% |
| 2022-12-31 | $-2.33 Million | -245.44% |
| 2021-12-31 | $-673.84K | +62.91% |
| 2020-12-31 | $-1.82 Million | -464.59% |
| 2019-12-31 | $-321.76K | -135.70% |
| 2018-12-31 | $901.31K | -68.71% |
| 2017-12-31 | $2.88 Million | +1140.83% |
| 2016-12-31 | $-276.75K | -115.54% |
| 2015-12-31 | $1.78 Million | -3.53% |
| 2014-12-31 | $1.85 Million | -4.33% |
| 2013-12-31 | $1.93 Million | +6.01% |
| 2012-12-31 | $1.82 Million | +16.74% |
| 2011-12-31 | $1.56 Million | -5.15% |
| 2010-12-31 | $1.64 Million | +457.91% |
| 2009-12-31 | $294.57K | +63.66% |
| 2008-12-31 | $179.99K | +91.42% |
| 2007-12-31 | $94.03K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biocure Technology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2382751400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $17.68 Million | 1318.45% |
| Other Components | $7.50 Million | 559.21% |
| Total Equity | $1.34 Million | 100.00% |
Biocure Technology Inc Competitors by Market Cap
The table below lists competitors of Biocure Technology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stelrad Group PLC
LSE:SRAD
|
$22.16K |
|
Tristel
LSE:TSTL
|
$22.16K |
|
SCAR3F
SA:SCAR3F
|
$22.17K |
|
VUZIX (V7XN.SG)
STU:V7XN
|
$22.17K |
|
IMDEX (IDG.SG)
STU:IDG
|
$22.13K |
|
CHINA RESOURCES GAS (LGX1.SG)
STU:LGX1
|
$22.11K |
|
CN TAIPING INSU
MU:HIUC
|
$22.11K |
|
PRNR3Q
SA:PRNR3Q
|
$22.10K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biocure Technology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,603,193 to 1,340,722, a change of -262,471 (-16.4%).
- Net loss of 262,471 reduced equity.
- Other comprehensive income decreased equity by 7,497,458.
- Other factors increased equity by 7,497,458.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-262.47K | -19.58% |
| Other Comprehensive Income | $-7.50 Million | -559.21% |
| Other Changes | $7.50 Million | +559.21% |
| Total Change | $- | -16.37% |
Book Value vs Market Value Analysis
This analysis compares Biocure Technology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $0.05 | $0.00 | x |
| 2008-12-31 | $0.20 | $0.00 | x |
| 2009-12-31 | $0.03 | $0.00 | x |
| 2010-12-31 | $0.07 | $0.00 | x |
| 2011-12-31 | $0.05 | $0.00 | x |
| 2012-12-31 | $0.06 | $0.00 | x |
| 2013-12-31 | $0.06 | $0.00 | x |
| 2014-12-31 | $0.05 | $0.00 | x |
| 2015-12-31 | $0.05 | $0.00 | x |
| 2016-12-31 | $-0.01 | $0.00 | x |
| 2017-12-31 | $0.04 | $0.00 | x |
| 2018-12-31 | $0.01 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $-0.02 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $-0.02 | $0.00 | x |
| 2023-12-31 | $0.02 | $0.00 | x |
| 2024-12-31 | $0.13 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biocure Technology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.49x
- Recent ROE (-19.58%) is above the historical average (-62.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -6.35% | 0.00% | 0.00x | 1.06x | $-15.37K |
| 2008 | -36.87% | 0.00% | 0.00x | 1.04x | $-84.37K |
| 2009 | -29.50% | 0.00% | 0.00x | 1.17x | $-116.34K |
| 2010 | -9.13% | 0.00% | 0.00x | 1.08x | $-314.35K |
| 2011 | -6.86% | 0.00% | 0.00x | 1.03x | $-262.88K |
| 2012 | -1.73% | 0.00% | 0.00x | 1.10x | $-213.41K |
| 2013 | 1.90% | 0.00% | 0.00x | 1.03x | $-156.17K |
| 2014 | -4.53% | 0.00% | 0.00x | 1.07x | $-268.10K |
| 2015 | -0.07% | 0.00% | 0.00x | 1.11x | $-179.24K |
| 2016 | 0.00% | -35304.41% | 0.01x | 0.00x | $-1.99 Million |
| 2017 | -165.88% | 0.00% | 0.00x | 1.35x | $-5.07 Million |
| 2018 | -730.76% | 0.00% | 0.00x | 4.02x | $-6.68 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.72 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.79 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.09 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.25 Million |
| 2023 | -113.15% | 0.00% | 0.00x | 1.23x | $-1.97 Million |
| 2024 | -19.58% | 0.00% | 0.00x | 1.49x | $-396.54K |
Industry Comparison
This section compares Biocure Technology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biocure Technology Inc (BICTF) | $1.61 Million | -6.35% | 0.26x | $22.14K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |